Organon and Co (OGN)

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA...

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Form SD - Specialized disclosure report

Organon présentera de nouvelles recherches sur l’accès et la valeur lors de l’ISPOR 2026

Ces nouvelles conclusions mettront en lumière l’accessibilité financière de la contraception, l’adoption des médicaments biosimilaires et des...

Organon to Present New Research on Access and Value at ISPOR 2026

New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general...

Form 144 - Report of proposed sale of securities

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Europäische Kommission erteilt Marktzulassung für POHERDY® (Pertuzumab) von Henlius und Organon, das erste in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab)

Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die Europäische Kommission die Zulassung für POHERDY®...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

La Commission européenne (CE) approuve le POHERDY® (pertuzumab) de Henlius et Organon, premier médicament biosimilaire du PERJETA (pertuzumab) autorisé en Europe

Shanghai Henlius Biotech, Inc. (2696.HK) et Organon (NYSE : OGN) a annoncé aujourd’hui que la Commission européenne (CE) a accordé une...